• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

可溶性尿激酶受体促进细胞黏附,并且激活p56/59(hck)需要酪氨酸92。

Soluble urokinase receptor promotes cell adhesion and requires tyrosine-92 for activation of p56/59(hck).

作者信息

Trigwell S, Wood L, Jones P

机构信息

School of Biomedical Sciences, Queens Medical Centre, University of Nottingham, Nottingham, NG7 2UH, United Kingdom.

出版信息

Biochem Biophys Res Commun. 2000 Nov 19;278(2):440-6. doi: 10.1006/bbrc.2000.3818.

DOI:10.1006/bbrc.2000.3818
PMID:11097855
Abstract

The urokinase plasminogen activator receptor (uPAR) plays an important role in the migration of leukocytes. It occurs as a membrane-bound form that contains a glycosylphosphatidylinositol (GPI) anchor and also as a soluble form (suPAR) that lacks the GPI anchor. Recently, a sequence of amino acids, SRSRYLE, within the receptor has been found to become unmasked on uPA binding or chymotrypsin cleavage. Exposure of the epitope results in the activation of p56/p59(hck) kinase and chemotaxis of myelomonocytic cells. Using an epitope-tagged suPAR molecule, we found that both three-domain and two-domain suPAR promote the adhesion of differentiated THP-1 cells to fibronectin and vitronectin, indicating that suPAR can modify cell adhesion as well as cell migration. In addition, we found that the amino acid sequence RYLE, within the chemotactic peptide, is conserved across species and that alanine substitution of Tyr 92 decreased the ability of the peptide to activate p56/59(hck).

摘要

尿激酶型纤溶酶原激活物受体(uPAR)在白细胞迁移中起重要作用。它以含有糖基磷脂酰肌醇(GPI)锚定的膜结合形式存在,也以缺乏GPI锚定的可溶性形式(suPAR)存在。最近,已发现该受体中的一段氨基酸序列SRSRYLE在uPA结合或胰凝乳蛋白酶切割时会暴露出来。表位的暴露导致p56/p59(hck)激酶的激活和骨髓单核细胞的趋化作用。使用表位标记的suPAR分子,我们发现三结构域和两结构域的suPAR均能促进分化的THP-1细胞与纤连蛋白和玻连蛋白的黏附,这表明suPAR既能调节细胞迁移,也能改变细胞黏附。此外,我们发现趋化肽中的氨基酸序列RYLE在物种间是保守的,并且Tyr 92的丙氨酸替代降低了该肽激活p56/59(hck)的能力。

相似文献

1
Soluble urokinase receptor promotes cell adhesion and requires tyrosine-92 for activation of p56/59(hck).可溶性尿激酶受体促进细胞黏附,并且激活p56/59(hck)需要酪氨酸92。
Biochem Biophys Res Commun. 2000 Nov 19;278(2):440-6. doi: 10.1006/bbrc.2000.3818.
2
A urokinase-sensitive region of the human urokinase receptor is responsible for its chemotactic activity.人尿激酶受体的一个尿激酶敏感区域负责其趋化活性。
EMBO J. 1997 Dec 15;16(24):7279-86. doi: 10.1093/emboj/16.24.7279.
3
Proteolytic cleavage of the urokinase receptor substitutes for the agonist-induced chemotactic effect.尿激酶受体的蛋白水解切割可替代激动剂诱导的趋化作用。
EMBO J. 1996 Apr 1;15(7):1572-82.
4
Urokinase receptor-dependent and -independent p56/59(hck) activation state is a molecular switch between myelomonocytic cell motility and adherence.尿激酶受体依赖性和非依赖性p56/59(hck)激活状态是骨髓单核细胞运动性和黏附性之间的分子开关。
EMBO J. 1999 Jun 1;18(11):3013-23. doi: 10.1093/emboj/18.11.3013.
5
Crystallization of soluble urokinase receptor (suPAR) in complex with urokinase amino-terminal fragment (1-143).可溶性尿激酶受体(suPAR)与尿激酶氨基末端片段(1-143)复合物的结晶。
Acta Crystallogr D Biol Crystallogr. 2005 Jun;61(Pt 6):697-700. doi: 10.1107/S0907444905014174. Epub 2005 May 26.
6
Random peptide bacteriophage display as a probe for urokinase receptor ligands.随机肽噬菌体展示作为尿激酶受体配体的探针
Biol Chem. 2002 Jan;383(1):149-58. doi: 10.1515/BC.2002.015.
7
Soluble urokinase receptor levels correlate with number of circulating tumor cells in acute myeloid leukemia and decrease rapidly during chemotherapy.可溶性尿激酶受体水平与急性髓系白血病循环肿瘤细胞数量相关,且在化疗期间迅速下降。
Cancer Res. 2000 Dec 15;60(24):7126-32.
8
The uPA receptor and the somatomedin B region of vitronectin direct the localization of uPA to focal adhesions in microvessel endothelial cells.尿激酶型纤溶酶原激活物(uPA)受体和玻连蛋白的生长调节素B区域将uPA定位于微血管内皮细胞的粘着斑。
Matrix Biol. 2007 Jun;26(5):359-70. doi: 10.1016/j.matbio.2007.01.009. Epub 2007 Feb 6.
9
An anti-urokinase plasminogen activator receptor (uPAR) antibody: crystal structure and binding epitope.一种抗尿激酶型纤溶酶原激活物受体(uPAR)抗体:晶体结构与结合表位
J Mol Biol. 2007 Jan 26;365(4):1117-29. doi: 10.1016/j.jmb.2006.10.059. Epub 2006 Oct 21.
10
Release of soluble urokinase receptor from vascular cells.血管细胞释放可溶性尿激酶受体。
Thromb Haemost. 2001 Aug;86(2):686-93.

引用本文的文献

1
Cleavage of the urokinase receptor (uPAR) on oral cancer cells: regulation by transforming growth factor - β1 (TGF-β1) and potential effects on migration and invasion.口腔癌细胞上尿激酶受体(uPAR)的裂解:转化生长因子-β1(TGF-β1)的调节作用及其对迁移和侵袭的潜在影响
BMC Cancer. 2017 May 19;17(1):350. doi: 10.1186/s12885-017-3349-7.
2
Hematopoietic cell kinase (HCK) as a therapeutic target in immune and cancer cells.造血细胞激酶(HCK)作为免疫细胞和癌细胞的治疗靶点。
Oncotarget. 2015 Jun 30;6(18):15752-71. doi: 10.18632/oncotarget.4199.
3
An uncleavable uPAR mutant allows dissection of signaling pathways in uPA-dependent cell migration.
一种不可切割的尿激酶型纤溶酶原激活物受体(uPAR)突变体可用于剖析uPA依赖性细胞迁移中的信号通路。
Mol Biol Cell. 2006 Jan;17(1):367-78. doi: 10.1091/mbc.e05-07-0635. Epub 2005 Nov 2.